Announced
Synopsis
Viva Biotech, a drug discovery platform, agreed to acquire an 80% stake in Langhua Pharmaceutical, a pharmaceutical company, for $367m. "The strategic acquisition agreement we made with Langhua Pharmaceutical will effectively improve the integrated service capability in new drug R&D and overall competitiveness for both sides. We have steady confidence towards the business prospects and potential future growth of Langhua Pharmaceutical," Mao Chen Cheney, Viva Biotech Chairman and CEO.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Bidder Team (1)
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
All rights reserved. Copyright © 2025 Datasite